Summary
56 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 66% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue growth is slowing: 5.9% a year over the last 3 years against 20% over 5 years.
- It reports a profit, yet spends more cash than it brings in.
- It earns only 3.9 CNY a year on every 100 CNY of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 26.7 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 20% a year over 5 years. Over the last 3 years it grew by 5.9% a year. Earnings per share grew by 66% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 CNY of revenue goes
- Cost of sales 79 CNY
- Research and development 2.2 CNY
- Sales and administration 13 CNY
- Taxes and other 2.2 CNY
- Net profit 3.9 CNY
Net profit, industry median (Chemicals - Specialty) 6.0 CNY
Out of every 100 CNY of revenue, 3.9 CNY is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail